“The Company is actively engaged with large, US based companies who are showing strong interest in the capability and performance of the system. The value proposition and competitive advantage for FRG based products in new and existing markets continues to strengthen.”
Ann: FRG Trials on Tuberculosis, page-242
Add PO3 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.078M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| PO3 (ASX) Chart |
Day chart unavailable
